ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2022
Complications, treatments, and visual prognosis of choroidal osteomas.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Differential diagnosis of myopic choroidal neovascularization (mCNV): insights from multimodal imaging and treatment implications.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Pooled it
- Optical Coherence Tomography Features and Multimodal Imaging Findings in Choroidal Osteoma: A Case Series.Ocular oncology and pathology · 2026Article
- Faricimab for choroidal neovascular membrane secondary to choroidal osteoma: A case report.The Journal of international medical research · 2026Article
- Outer retinal tubulation associated with photoreceptor degeneration.Progress in retinal and eye research · 2026Review
- Case Report: Faricimab in the treatment of subretinal fluid secondary to choroidal osteoma without definite evidence of CNV.Frontiers in medicine · 2026Article
- Article
- Prevalence and clinical correlates of focal choroidal excavation in a large cohort of Chinese patients with choroidal osteoma.Eye and vision (London, England) · 2025Article
- Serous retinal detachment secondary to bilateral choroidal osteoma successfully treated with subscleral sclerectomy: A case report.American journal of ophthalmology case reports · 2025Article
- 10-Year follow-up for hemorrhagic choroidal osteoma.Eye (London, England) · 2025Article
- Inhibition of choroidal osteoma progression using bisphosphonate and RANKL-inhibitory treatment.American journal of ophthalmology case reports · 2024Article
- Article
- Spontaneous Resolution of Subretinal Detachment in Choroidal Osteoma Unresponsive to Antivascular Endothelial Growth Factor Agent and Multimodal Imaging: A Case Report.Korean journal of ophthalmology : KJO · 2023Article
- Case Report: Vision-threatening manifestations of choroidal osteomas and papilloedema in presumed Camurati-Engelmann disease.Frontiers in neurologyArticle
- Bilateral Choroidal Osteomas in an Elderly Woman: A Case Report.Case reports in ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
purposeThis study aims to report complications, treatments, and visual prognosis of choroidal osteoma.
methodsWe retrospectively reviewed electronic medical records and multimodal images of 41 patients with choroidal osteoma.
resultsVisually significant complications included choroidal neovascularization (CNV) in 21 (47.7%) eyes and subretinal fluid (SRF) without CNV in 14 (31.8%) eyes. The most common treatment was intravitreal anti-vascular endothelial growth factor (VEGF) injection: 13 (61.9%) eyes with CNV received an average of 6.3 injections, and 6 (42.9%) eyes with SRF but without CNV received 1.8 injections. As the first-line treatment, intravitreal anti-VEGF injection induced complete or partial remission in 93.4% of eyes with CNV and 57.1% of eyes with SRF. The probability of legally low vision estimated at 3 and at 5 years was 29.1% and 34.2%, respectively. The presence of CNV and outer retinal tubulation (ORT) was independent risk factors for vision loss (adjusted odds ratio, 8.08 and 6.94, respectively).
conclusionsThe development of CNV and ORT was strong risk factors for visual impairment. Due to the frequent recurrence of complications and poor visual prognosis, regular check-ups and appropriate treatment choices are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.